Modified Vaccinia Ankara Bavarian Nordic (MVA-BN) as a smallpox and mpox vaccine has been approved in its liquid-frozen (LF) formulation in the US, Canada, and EU. A freeze-dried (FD) formulation may offer additional benefits, such as a longer shelf life and reduced dependence on cold chain storage and transport. In a phase 2 clinical trial, 651 vaccinia-naïve participants were vaccinated with two doses of MVA-BN LF or FD, 4 weeks apart. The objectives were to compare MVA-BN FD with LF in terms of vaccine-induced immune responses, safety, and reactogenicity. Non-inferiority of the immune response was assessed by the 95% CI of the geometric mean ratios. Both formulations induced robust vaccinia-specific humoral and cellular immune responses. At peak humoral responses (Week 6), geometric means of total antibody titers were 1096 (95% CI 1013, 1186) from the FD group and 877 (95% CI 804, 956) from the LF group, achieving the primary endpoint of non-inferiority of MVA-BN FD compared to MVA-BN LF. At peak cellular responses (Week 2), geometric means of T cell spot forming units were 449 (95% CI 341, 590) from the FD group and 316 (95% CI 234, 427) from the LF group. Both formulations of MVA-BN were well tolerated, with similar unsolicited AEs and solicited systemic reactions in both groups but slightly more local reactions in the FD group. No vaccine-related serious adverse events (SAEs) or vaccine-related AE of special interest were reported. The FD formulation of MVA-BN was shown to be equivalent to MVA-BN LF.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11346558 | PMC |
http://dx.doi.org/10.1080/21645515.2024.2384189 | DOI Listing |
Emerg Microbes Infect
December 2025
Bordeaux Population Health Research Centre, Université de Bordeaux, Inserm, and Inria, Bordeaux, France.
rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo are WHO-prequalified vaccination regimens against Ebola virus disease (EVD). Challenges associated with measuring long-term clinical protection warrant the evaluation of immune response kinetics after vaccination.
View Article and Find Full Text PDFMed Klin Intensivmed Notfmed
November 2024
Medizinische Klinik II, Kardiologie, Angiologie, Internistische Intensivmedizin, St. Marien-Krankenhaus Siegen, Kampenstr. 51, 57072, Siegen, Deutschland.
Mpox (previously known as monkeypox) is receiving attention worldwide due to outbreaks in various countries since May 2022. On August 14, 2024, based on the increase Mpox infections, the World Health Organization (WHO) declared a public health emergency. The zoonotic disease is caused by the Mpox virus, an Orthopoxvirus related to other Poxviridae.
View Article and Find Full Text PDFRev Bras Enferm
October 2024
Universidade de Brasília. Brasília, Distrito Federal, Brazil.
Objectives: to analyze the vaccination situation against Mpox in people living with HIV/AIDS in Brazil.
Methods: an ecological study on the vaccination status against Mpox in people living with HIV/AIDS (PLWHA) in Brazil. The data were collected in April 2023 through information from the Ministry of Health, using the "Microsoft app Power BI," which is publicly accessible.
Vaccine
December 2024
Bavarian Nordic, Bavarian Nordic Switzerland AG, Zug, Switzerland.
New Microbes New Infect
December 2024
Faculty of Health Sciences, Universidad Científica Del Sur, Lima, 15067, Peru.
The recent global resurgence of Mpox (formerly monkeypox), primarily transmitted via close contact and respiratory droplets, highlights a significant shift in its epidemiology, particularly among men who have sex with men (MSM). This resurgence underscores the need for robust public health responses and improved surveillance. This comprehensive review of current literature focuses on recent outbreaks, virology, and available treatments.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!